Hims & Hers (HIMS) Soars on Eli Lilly Partnership — Wall Street Takes Notice

Table of Contents Shares of Hims & Hers Health surged 7% Thursday following the telehealth platform’s announcement that it would integrate weight management medications from pharmaceutical giant Eli Lilly. Hims & Hers Health, Inc., HIMS Healthcare professionals utilizing the Hims & Hers network now have the ability to prescribe Zepbound vials, KwikPen devices, and Foundayo products. Patients can obtain these prescriptions via the LillyDirect pharmacy service, with self-pay pricing structures made available to platform users. The integration provides licensed medical practitioners with streamlined access to FDA-authorized GLP-1 therapeutic options for their patients. This partnership announcement comes on the heels of a collaboration unveiled in recent weeks with Novo Nordisk. That agreement enabled platform subscribers to access Wegovy injectable formulations and oral medication alternatives. Combined, these strategic alliances signal a significant transformation in the organization’s approach to weight management services in the United States. Company representatives attribute the strategic shift to escalating consumer demand and evolving marketplace conditions surrounding GLP-1 pharmaceutical products. The comprehensive weight management program encompasses round-the-clock care team availability, customized nutritional guidance, ongoing clinical monitoring, and community-based support through its Weight Loss member network. According to company statements, the objective centers on providing diverse therapeutic alternatives customized to each patient’s unique medical background and wellness objectives. The equity received additional momentum Friday when J.P. Morgan launched coverage with an “Overweight” designation and established a $35 valuation target. Analysts identified the Novo Nordisk collaboration as a pivotal development for the weight management division, noting it diminishes regulatory exposure associated with compounded GLP-1 products while expanding availability of brand-name therapies. J.P. Morgan forecasts HIMS will surpass 100,000 monthly Wegovy prescriptions, potentially generating an annualized revenue stream of approximately $350–$400 million from this single product line. The investment bank also identified peptide-based therapeutics as a substantial long-term expansion avenue. With federal regulators potentially authorizing mass compounding for multiple peptide formulations, Hims & Hers’ internal manufacturing capabilities could position it favorably. J.P. Morgan anticipates revenues expanding from $2.3 billion in 2025 to surpass $3.2 billion by 2027, with EBITDA reaching $414 million. Company leadership has set targets for sustained annual revenue expansion exceeding 20% through the end of the decade. Revenue acceleration is anticipated during the latter half of 2026 as emerging specialty categories mature and branded product offerings enhance customer financial metrics. However, headwinds persist. The equity ranks among the most heavily shorted within its sector. Market participants express concerns regarding growth deceleration, escalating customer acquisition expenses, and intensifying competition from Amazon and competing telehealth provider Ro. J.P. Morgan recognized these challenges but concluded that current market valuation inadequately captures the organization’s expansion prospects. HIMS currently supports roughly 2.5 million subscribers spanning weight management, sexual wellness, and dermatological services. Its fully integrated operational structure—encompassing medical providers, pharmaceutical dispensaries, and production facilities—was emphasized by J.P. Morgan as a fundamental competitive differentiator. At the time of writing, Novo Nordisk (NVO) was up 5.53% and Eli Lilly (LLY) was down 2.84% on the day.